Combined Hormonal Contraception Study Notes

Combined Hormonal Contraception (CHC) Overview and Active Components

  • Definition & Composition:

    • Combined Hormonal Contraception (CHC) consists of estrogen-progestin combination products.
    • Synthetic Estrogen Component: Ethinyl estradiol.
    • Progestin Component: Variable generations of progestin compounds.
  • Primary Purpose of Medication:

    • Prevent pregnancy.
    • Control symptoms related to menstruation.
    • Clinical outcome: Most women experience lighter, shorter periods and decreased uterine cramps.
  • Core Cardiovascular Risk Summary:

    • Estrogen increases blood clotting risks, directly predisposing patients to venous thromboembolism (VTE), myocardial infarction (MI), and stroke.

Pharmacological Mechanisms of Action

  • Estrogen Actions:

    • Prevents the formation of a dominant follicle.
    • Prevents ovulation.
    • Prevents the luteinizing hormone (LH) surge.
    • Stabilizes the uterine endometrium.
    • Inhibits proliferation and secretory endometrial changes.
    • Decreases irregular and/or heavy menstruation.
  • Progestin Actions:

    • Balances the physiological effects of estrogen.
    • Makes the endometrium less favorable for blastocyst implantation.
    • Suppresses the LH surge.
    • Prevents ovulation and pregnancy.

Adverse Effects and Hormonal Complications

  • Increased Estrogen Effects:

    • Cyclic breast changes and tender breasts.
    • Dysmenorrhea.
    • Menorrhagia.
    • Chloasma (hyperpigmentation).
    • Venous Thromboembolism (VTE).
  • Decreased Estrogen Effects:

    • Amenorrhea.
    • Spotting.
  • Increased Progestin Effects:

    • Weight gain.
    • Depression.
    • Fatigue.
    • Decreased libido.
  • Decreased Progestin Effects:

    • Breakthrough bleeding.
    • Headaches.
  • Complications from Higher Estrogen Doses:

    • Increased risk of myocardial infarction (MI).
    • Increased risk of venous thromboembolism (VTE).
    • Increased risk of stroke.

Contraindications, Precautions, and Drug Interactions

  • Contraindications & Precautions:

    • Women older than 35 years35\text{ years} who smoke: High risk of increased VTE.
    • Drospirenone (Yasmin) Specific Contraindications:
      • Liver insufficiency.
      • Kidney insufficiency.
      • Adrenal insufficiency.
      • Long-term concurrent use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
      • Long-term concurrent use with potassium-sparing diuretics.
      • Long-term concurrent use with Angiotensin-Converting Enzyme (ACE) inhibitors.
      • Long-term concurrent use with Angiotensin Receptor Blockers (ARBs).
  • Drug Interactions:

    • Antibiotics: Can interfere with oral contraceptive efficacy; patients must use non-hormonal backup contraception while taking antibiotics.
    • Yasmin + Potassium-Increasing Drugs: Concurrent use increases K+K^+ levels, posing a severe risk of hyperkalemia. Hyperkalemia can lead to lethal cardiac events, including ventricular arrhythmias and ventricular tachycardia (V-tach).

Administration Routes, Regimens, and Missed-Dose Protocols

  • General Administration Routes:

    • Oral.
    • Transvaginal.
    • Transdermally.
  • Oral Contraceptive Regimens:

    • Most common route worldwide due to ease of use.
    • Supplied in 21-day21\text{-day} or 28-day28\text{-day} packs.
    • Consists of 21 days21\text{ days} of active hormone pills followed by either no pills or 7 inactive pills7\text{ inactive pills} for the final 7 days7\text{ days}.
    • The last 7 days7\text{ days} trigger withdrawal bleeding.
  • Transdermal Patch (Ortho-Evra):

    • Application Sites: Stomach, buttocks, outer arm, or upper torso.
    • Site Management: Sites must be rotated continuously. Skin must be clean, dry, and free from hair. Do not cut the patch.
    • Schedule: Patch is worn for 3 weeks3\text{ weeks} continuously, followed by 1 week1\text{ week} off (withdrawal bleeding occurs).
    • Weight Limitation: Reduced efficacy in women weighing more than 198 lb198\,\text{lb}.
  • Transvaginal Ring (NuvaRing):

    • Structure: A 2-inch2\text{-inch} indwelling flexible ring containing estrogen and progestin.
    • Insertion Schedule: Inserted into the vagina during the first 5 days5\text{ days} of menstruation. Remains in place for 3 weeks3\text{ weeks}, then removed for 1 week1\text{ week} off (withdrawal bleeding occurs).
    • Displacement Protocol: If the ring falls out, it must be reinserted within 3 hours3\text{ hours}. If out for more than 3 hours3\text{ hours}, a backup contraceptive method must be used for 7 days7\text{ days}.
  • Nursing Interventions for Missed Oral Pills:

    • Miss 1 tablet1\text{ tablet}: Take the missed tablet as soon as remembered.
    • Miss 2 tablets2\text{ tablets}: Take 2 tablets2\text{ tablets} as soon as remembered, take 2 tablets2\text{ tablets} the next day, and use backup non-hormonal contraception for the remainder of the cycle.
    • Miss 3 tablets3\text{ tablets}: Discard the pill pack entirely and restart.

Comparison of Ortho-Evra Transdermal Patch and NuvaRing

Ortho-Evra Patch vs NuvaRing comparison table

  • Ortho-Evra Patch Specifications:

    • Route: Transdermal.
    • Duration: 3 weeks3\text{ weeks}.
    • Off Period: 1 week1\text{ week}.
    • Main Concerns: Skin irritation, VTE, nausea, cramps.
    • Smoking Hazard: Increased VTE risk.
    • Weight Constraint: Less effective in patients exceeding 198 lb198\,\text{lb}.
  • NuvaRing Specifications:

    • Route: Transvaginal.
    • Duration: 3 weeks3\text{ weeks}.
    • Off Period: 1 week1\text{ week}.
    • Main Concerns: VTE, vaginal irritation, discharge/infection.
    • Smoking Hazard: Increased VTE risk.
    • Displacement Constraint: Replace within 3 hours3\text{ hours} if displaced.

Clinical Efficacy, Therapeutic Uses, and Patient Education

  • Efficacy Rates:

    • 99.3%99.3\% effective with absolute correct (perfect) use.
    • 92%92\% effective with typical use.
    • Crucial Limitation: CHCs do NOT protect against Sexually Transmitted Infections (STIs).
  • Evaluation of Medication Effectiveness:

    • Prevention of pregnancy.
    • Decreased menstrual blood loss.
    • Decreased uterine cramps.
    • Elimination of mittelschmerz (pain associated with ovulation).
    • Reduction of irregular and/or heavy menstruation.
  • Non-Contraceptive Therapeutic Uses:

    • Decreased blood loss and menstrual cramps.
    • Elimination of mittelschmerz.
    • Reduction of ovarian cysts.
    • Reduction of benign breast disorders.
    • Reduction of pelvic inflammatory disease (PID).
    • Reduction of ectopic pregnancies.
  • Patient Education Guidelines:

    • Reinforce that CHCs afford zero protection against STIs.
    • Instruct patient to use secondary backup contraception if prescribed antibiotics.
    • Adhere strictly to missed-dose protocols.
    • Rotate transdermal patch sites and never cut a transdermal patch.
    • Replace a fallen NuvaRing within 3 hours3\text{ hours} or maintain backup contraception for 7 days7\text{ days}.
    • Warn patients that smoking significantly escalates VTE risk.
    • Advise using the lowest possible estrogen dose to mitigate serious systemic adverse effects.

Classification of Estrogens and Progestin Generations

  • Estrogen Dosage Guidelines:

    • Lower-estrogen formulations containing estradiol are preferred in modern clinical practice.
    • Always utilize the lowest effective dose.
    • Higher estrogen concentrations directly correlate with increased risks of MI, VTE, and stroke.
    • Mestranol is a synthetic estrogen used primarily in older formulations or high-concentration products.
  • Generational Breakdown of Progestins:

    • 1st1\text{st} Generation: Norethindrone, Norethindrone acetate, Ethynodiol.
    • 2nd2\text{nd} Generation: Norethisterone, Levonorgestrel (LNG - most common progestin component).
    • 3rd3\text{rd} Generation: Desogestrel, Gestodene, Norgestimate.
    • Generational Progression Trends: Higher progestin generations demonstrate higher contraceptive efficacy, fewer adverse metabolic/lipid impacts, and significantly reduced androgenic side effects.

Phasic Oral Formulations and Specific Contraceptive Products

  • Phasic Oral Categories:

    • Monophasic: Contains a fixed ratio of estrogen and progestin throughout the entire active cycle.
    • Biphasic: Features a fixed amount of estrogen with lower progestin levels early in the cycle, permitting normal physiological menstruation processes without ovulation (Example: Ortho-Novum).
    • Triphasic: Delivers low total doses of estrogen and progestin with altered ratios across 3 distinct phases3\text{ distinct phases}; minimizes side effects (Example: Ortho Tri-Cyclen Lo, which is also indicated for acne treatment).
    • Four-phasic: Delivers varying doses of estradiol valerate and dienogest across four distinct phases; newest class designed to closely mimic physiological hormone ratios.
  • Specific Brand Formulations & Clinical Profiles:

    • Yasmin: Monophasic oral contraceptive consisting of ethinyl estradiol and drospirenone. Drospirenone is a spironolactone analogue with potassium-sparing properties, carrying a risk of hyperkalemia and secondary V-tach/ventricular arrhythmias.
    • Loestrin FE: Formulated with supplemental iron (Fe\text{Fe}) during the inactive pill period to combat iron-deficiency anemia from withdrawal bleeding.
    • Mircette: Features 2 days2\text{ days} of iron (Fe+\text{Fe}+) and 5 days5\text{ days} of low-dose estrogen during the off-period to prevent estrogen-withdrawal headaches.
  • Extended-Cycle and Continuous Formulations:

    • Physiological Note: Withdrawal bleeding on CHCs is artificially induced and is not a true physiological menstrual period; it is not medically necessary.
    • Extended-Cycle Products: Shorten inactive pill intervals to minimize total withdrawal bleeding days (Examples: Loestrin 24, YAZ, Beyaz).
    • Continuous Dosing Products:
      • Seasonale / Jolessa: 91-day91\text{-day} regimen composed of 84 active pills84\text{ active pills} followed by 7 inactive pills7\text{ inactive pills}, resulting in withdrawal bleeding only 4 times per year4\text{ times per year}.
      • Lybrel: 28-day28\text{-day} continuous active formulation that eliminates withdrawal bleeding entirely.